Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Impact of pulmonary hypertension on in-hospital outcomes among patients hospitalized with multiple myeloma: A 2015–2022 national inpatient sample analysis

Faizan Ahmed, Haziq Ahmad, Haris Tahir, Najam Gohar, Muhammad Ibrahim, Aleena Khan, Aftab Gohar, Saboor Randhawa, Tehmasp Mirza, Faseeh Haider, Ramsha Ali, Salman Fazal

Blood (2025) 146 (Supplement 1): 5805.

https://doi.org/10.1182/blood-2025-5805

Published: 2025

Journal Articles

Impact of continuous lenalidomide on second primary malignancies in patients with multiple myeloma

Mohammad Ebad Ur Rehman, Samra Sohail, Bana Antonios, Eiraj Khan, Nina Dutton, Jennifer Dujmic, Salman Fazal

Blood (2025) 146 (Supplement 1): 7570.

https://doi.org/10.1182/blood-2025-7570

Published: 2025

Journal Articles

Trends and predictors of inpatient mortality in patients with aplastic anemia: A 7-year national inpatient sample analysis

Najam Gohar, Muhammad Usman, Haris Tahir, Fatima Ali, Muhammad Ibrahim, Haziq Ahmad, Saboor Randhawa, Faizan Ahmed, Tehmasp Mirza, Faseeh Haider, Ramsha Ali, Salman Fazal

Blood (2025) 146 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2025-6724

Published: 2025

Journal Articles

Trends in second primary malignancies in myelofibrosis pre- and post-JAK inhibitor era: A surveillance, epidemiology and end-Results database study

Mohammad Ebad Ur Rehman, Samra Sohail, Bana Antonios, Eiraj Khan, Nina Dutton, Jennifer Dujmic, Salman Fazal

Blood (2025) 146 (Supplement 1): 3825.

https://doi.org/10.1182/blood-2025-3825

Published: 2025

Journal Articles

Trends and disparities in infection-related mortality among non-Hodgkin lymphoma patients in the United States, 1999–2023

Muhammad Waseem Tahir, Zubia Tahir, Abigail Emerson, Saira Chaughtai, Ranju Kunwor, Aman Ullah, Muhammad Bilal, Zaheer Qureshi, Ali Bhatti, Diljot Singh, Moazzam Shahzad, Salman Fazal, FNU Veena, Sherif Eltawansy, Muneeba Syed, Junaid Saleem

Blood (2025) 146 (Supplement 1): 8046.

https://doi.org/10.1182/blood-2025-8046

Published: 2025

Journal Articles

Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study

Naveen Pemmaraju, Ellen Ritchie, John Mascarenhas, Salman Fazal, Erin Crowgey, TaeHyung (Simon) Kim, J.E. Hamer-Maansson, Tricia Kalafut, Evan Braunstein, Abdulraheem Yacoub

Blood (2025) 146 (Supplement 1): 5526.

https://doi.org/10.1182/blood-2025-5526

Published: 2025

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Blood (2021) 138 (Supplement 1): 66.

https://doi.org/10.1182/blood-2021-144648

Published: 2021

Journal Articles

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Roger Lyons, David Lessen, Salman Fazal, Robyn Scherber, Patricia Kalafut, Haobo Ren, Ellen Ritchie

Blood (2021) 138 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2021-145909

Published: 2021

Journal Articles

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben A. Mesa, Claire N. Harrison, Giovanni Barosi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Vishwanath Gharpure, Christopher Hernandez, Tianhua Wang, Moshe Talpaz

Blood (2021) 138 (Supplement 1): 389.

https://doi.org/10.1182/blood-2021-147607

Published: 2021

Journal Articles

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood (2021) 138 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2021-150277

Published: 2021

Journal Articles

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa Reddy R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Zoe Mckinnell, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 1264.

https://doi.org/10.1182/blood-2021-153791

Published: 2021

Journal Articles

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Urwat Til Vusqa, Palash Asawa, Maitreyee Rai, Yazan Samhouri, Prerna Mewawalla, Anna Koget, Santhosh Sadashiv, Cyrus Kahn, Salman Fazal, John Lister

Blood (2021) 138 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2021-151113

Published: 2021

Journal Articles

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Blood (2021) 138 (Supplement 1): 3682.

https://doi.org/10.1182/blood-2021-154179

Published: 2021

Journal Articles

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari, MD MRCP, Haris Ali, MD, Yi-Bin Chen, MD, Salman Fazal, MD, Tara K. Gregory, MD, Sarah M. Anand, MD, Ahmad Naim, MD, Dilan Paranagama, PhD, Valkal Bhatt, PharmD, Amy Blithe, RD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140541

Published: 2020

Journal Articles

Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis

Yazan Samhouri, MD, Thejus Jayakrishnan, MBBS, Lynna Alnimer, MD, Deanna Huffman, DO, Veli Bakalov, MD, Rodney E Wegner, MD, Salman Fazal, MD, Cyrus Kahn, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137317

Published: 2020

Journal Articles

Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review

Muhammad Salman Faisal, MD MBBS, Laila Hashim, MBBS, Yazan Samhouri, MD, Syed Maaz Abdullah, MBBS, Ahsan Wahab, MD, Moazzam Shahzad, MD, Hamid Ehsan, MDMBBS, Zahoor Ahmed, MD, Karun Neupane, MBBS,MD, Asim Tameez Ud Din, MD MBBS, Faiz Anwer, MD, Salman Fazal, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-138616

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of pulmonary hypertension on in-hospital outcomes among patients hospitalized with multiple myeloma: A 2015–2022 national inpatient sample analysis

Impact of continuous lenalidomide on second primary malignancies in patients with multiple myeloma

Trends and predictors of inpatient mortality in patients with aplastic anemia: A 7-year national inpatient sample analysis

Trends in second primary malignancies in myelofibrosis pre- and post-JAK inhibitor era: A surveillance, epidemiology and end-Results database study

Trends and disparities in infection-related mortality among non-Hodgkin lymphoma patients in the United States, 1999–2023

Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis

Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only